Full-Time

Senior Medical Science Liaison

Oncology

Posted on 11/3/2025

Deadline 12/19/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$149.9k - $181.6k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Remote in USA

Hybrid

Must live within 50 miles of territory; 50-70% travel; field-based; territory includes MN, WI, IA, IL, IN, MI, OH, KY.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Requirements
  • Doctorate degree preferred (PhD, PharmD, MD, DO); Advanced Nursing Degree; Advanced Degree in Health Sciences; Master of Science or equivalent; current licensure in respective field, if applicable
  • Minimum of 5-8 years of oncology Medical Science Liaison experience with a radiopharmaceutical or solid tumor product
  • Excellent interpersonal communication and presentation skills (including ability to network)
  • Disease area knowledge and an understanding of scientific publications, clinical and competitive landscape and patient treatment trends
  • Ability to translate scientific or clinical data into an understandable and valuable form to help physicians best serve their patients
  • Excellent teaching skills and ability to present and discuss scientific material clearly and concisely
  • Proven ability to create and sustain relationships with industry leaders
  • Skilled in clinical research and understand the process of pharmaceutical product development and approval
  • Demonstrated ability to organize, prioritize, and work effectively with minimal supervision in a constantly changing environment
  • Able to function in a highly regulated environment and to adhere to all RayzeBio guidelines and standard operating procedures (SOPs), while responding to a variety of questions and requests from healthcare professionals
  • Solid understanding of Good Clinical Practice (GCP) and International Conference on Harmonisation (ICH) guidelines
  • Current working knowledge of U.S. legal, regulatory, and compliance regulations relevant to industry interactions with healthcare professionals
  • Demonstration of Bristol Myers Squibb/RayzeBio values
  • Excellent English language skills, spoken and written
  • Travel: Travel required 50-70% of the time; Evening and weekend work; occasional international travel; Field-based role; live in territory or within 50 miles of territory borders; coverage includes MN, WI, IA, IL, IN, MI, OH, KY and subject to change
  • Ability to drive a company-provided car and maintain ethical driving history
Responsibilities
  • Develop and maintain relationships with academic and community health care professionals within an assigned territory, providing credible, fair balanced, scientific information about RayzeBio products (unsolicited product requests), research activities, and product development; use 1:1, group presentations, remote, congress meetings, etc.
  • Demonstrate proficiency in the specialized area of Radiopharmaceutical Therapy by using available scientific resources such as training materials and other approved scientific resources and presentations; communicate this information to KOLs/HCPs and respond to questions while ensuring medical accuracy and compliance with local procedures and company ethical and legal guidance
  • Be a therapeutic area and product/compound expert through regular review of literature and participation in scientific congresses and conferences; educate internal teams on KOLs, site profiling, and ongoing research
  • Proactively build healthcare provider support by employing a scientific approach that aligns with medical affairs objectives and the therapeutic area medical plan; contribute to the development of Key Opinion Leaders within the therapeutic area and serve as a major source of balanced medical information on RayzeBio products; manage safety and off-label use issues based on best available data
  • Territory planning as a dynamic activity considering radiopharmaceutical target, target life cycle, therapeutic area, and territory; liaise with internal stakeholders to build an action-oriented plan
  • Attend national and international congresses and local/regional meetings; collect and provide meaningful medical insights by communicating these back to the medical and clinical organizations to support strategy development
  • Play a role in internal training and communication with the medical affairs, brand team, and territory managers; knowledge sharing on KOLs, site profiling, and education internally and externally
  • Proactively collaborate with cross-functional teams, ensuring compliance, customer-centric interactions, and ongoing medical/scientific training for internal/external stakeholders groups
  • Contribute to the development of RayzeBio’s therapeutic products by offering strategic input to internal stakeholders and facilitating understanding of the clinical landscape
  • Engage in various clinical trial activities, providing recommendations on study and site feasibility based on direct field knowledge and relationships with potential investigators; provide insights via territory profiling and external meetings with KOLs/HCPs; collaborate with clinical development, clinical operations, and medical affairs leadership
  • Play a strategic role in pre-launch and peri-launch activities, ensuring medical plans and product strategies are developed in alignment with disease area, product lifecycle, and market needs
  • Support KOLs/HCPs in the discussion, submission and execution of the RayzeBio Investigator Initiated Trial process based on existing policy and procedures
  • Support CRO sponsored studies as agreed with leadership of clinical development and medical affairs

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE